RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
Method for safe and sustainable recycling of waste The method developed by RIVM to assess whether waste treatment is sufficiently safe and sustainable, can contribute to the European ambitions for a safe and more circular economy.
COVID-19 consequences impact vulnerable groups more in the long term The effects of the corona crisis have a greater impact on vulnerable groups in society, such as lower-educated adults, young people, the elderly and people with underlying health problems.
Increase in gonorrhoea and syphilis diagnoses The number of people who got themselves tested for a sexually transmitted infection (STI) at a Sexual Health Centre (SHC) in 2019 has remained almost the same as in 2018.
State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.
A guide for the safe reuse of diaper and incontinence materials RIVM has developed a step-by-step plan for the safe reuse of diapers and incontinence material. This plan provides recyclers and licensing authorities with tools to carry out a risk assessment.
Emphasising safety and sustainability in circular design A stronger focus on safety, health and sustainability is needed in designing circular products. When basic resources are re-used in new products, health risks should be avoided.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Teen vaccination against meningococcal disease starts From mid-September, young people born between 1 May and 31 December 2004 will receive an invitation for a vaccination against meningococcal disease.